Bleximenib oxalate

Bleximenib (JNJ-75276617) oxalate is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib oxalate can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib oxalate can be used in the research of tumors such as leukemia.


Cat. No.: EX-A8746	Purity: >98%

	Chemical structure of Bleximenib oxalate

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	985	In-stock
250mg	1788	In-stock
500mg	3150	In-stock
1g	5450	In-stock
2g	get quote	In-stock
3g	get quote	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	2866179-95-3
Purity	>98%
Formula	C34H52FN7O7
Mol Weight	689.8178
Color	Off-white to light yellow
State	solid powder
Solubility	DMSO : 100 mg/mL H2O : 50 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Kwon MC, et al. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood. 2024 Sep 12;144(11):1206-1220. [2]. Hogeling SM, et al. Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia. Haematologica. 2024 Dec 19.
CoA	CoA of Bleximenib oxalate


		Search